|
gptkbp:instance_of
|
gptkb:virus
|
|
gptkbp:bfsLayer
|
5
|
|
gptkbp:bfsParent
|
gptkb:varicella-zoster_virus
gptkb:Herpesviridae
gptkb:herpesviridae_family
|
|
gptkbp:age
|
12 months and older
|
|
gptkbp:caused_by
|
chickenpox
shingles
|
|
gptkbp:complications
|
gptkb:healthcare_organization
gptkb:physicist
gptkb:psychologist
thrombocytopenia
|
|
gptkbp:contraindication
|
pregnancy
immunocompromised individuals
severe allergic reaction
|
|
gptkbp:first_described_by
|
gptkb:Thomas_Weller
|
|
gptkbp:genetic_diversity
|
one serotype
|
|
gptkbp:genus
|
gptkb:Varicellovirus
|
|
gptkbp:healthcare
|
herd immunity
outbreaks
|
|
gptkbp:hosts
|
gptkb:Person
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
VZV
|
|
gptkbp:incubation_period
|
10 to 21 days
|
|
gptkbp:is_a
|
gptkb:herpesvirus
|
|
gptkbp:is_protected_by
|
vaccination
|
|
gptkbp:is_recognized_by
|
human patients
|
|
gptkbp:is_vulnerable_to
|
gptkb:varicella_vaccine
over 90%
fever
two doses
subcutaneous injection
live attenuated vaccine
zoster vaccine
mild rash
tenderness at injection site
|
|
gptkbp:nutritional_value
|
gptkb:Herpesviridae
|
|
gptkbp:pharmacokinetics
|
gptkb:valacyclovir
gptkb:acyclovir
gptkb:famciclovir
|
|
gptkbp:related_to
|
gptkb:herpes_simplex_virus
|
|
gptkbp:restoration
|
shingles
|
|
gptkbp:risk_factor
|
stress
certain medications
immunocompromised state
age over 50
|
|
gptkbp:seed_dispersal
|
double-stranded DNA
|
|
gptkbp:social_responsibility
|
clinical examination
serological tests
PCR testing
dorsal root ganglia
|
|
gptkbp:symptoms
|
fever
rash
1 to 2 weeks
itching
|
|
gptkbp:transmission
|
direct contact
airborne droplets
|
|
gptkbp:treatment
|
gptkb:drug
symptomatic relief
early intervention recommended
|
|
gptkbp:year_created
|
gptkb:1954
|